JAK3 Antibody (3F228): sc-71461
- JAK3 Antibody (3F228) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against amino acids 1076-1100 of JAK3 of mouse origin
- recommended for detection of JAK3 of mouse, rat and human origin by WB, IP, IF and IHC(P); non cross-reactive with JAK 1, JAK 2 or Tyk 2
- See JAK3 (B-12): sc-6932 for JAK3 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for JAK3 Antibody (3F228). This work is in progress.
QUICK LINKS
JAK3 Antibody (3F228) is a mouse monoclonal IgG2a antibody that detects JAK3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-JAK3 antibody (3F228) plays a crucial role in the regulation of the JAK/Stat signaling pathway, which is essential for maintaining a balanced immune response. JAK3 is primarily located in the cytoplasm of hematopoietic cells, where JAK3 associates with cytokine receptors and is activated upon cytokine binding. This localization is vital because JAK3 can rapidly respond to extracellular signals, facilitating the phosphorylation of Stat transcription factors. Once activated, these Stat factors dimerize and translocate to the nucleus, where Stat factors regulate the transcription of genes involved in immune cell proliferation, differentiation, and survival. Dysregulation of JAK3 activity can lead to various immune disorders, making JAK3 an important target for therapeutic intervention in inflammatory diseases. JAK3 (3F228) antibody is an invaluable tool for researchers studying the intricate mechanisms of immune regulation and the potential for developing targeted anti-inflammatory therapies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
JAK3 Antibody (3F228) References:
- Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. | Lin, TH., et al. 2010. Arthritis Rheum. 62: 2283-93. PMID: 20506481
- 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. | Soth, M., et al. 2013. J Med Chem. 56: 345-56. PMID: 23214979
- The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells. | Wang, H., et al. 2013. J Immunol. 191: 1164-74. PMID: 23797672
- Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. | Forster, M., et al. 2017. Bioorg Med Chem Lett. 27: 4229-4237. PMID: 28844493
- Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. | Degryse, S., et al. 2018. Blood. 131: 421-425. PMID: 29187379
- PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. | Yuan, S., et al. 2022. Leukemia. 36: 370-382. PMID: 34465864
- Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. | Long, Q., et al. 2022. J Adv Res. 40: 153-166. PMID: 36100323
- Suppression of NK Cell Activation by JAK3 Inhibition: Implication in the Treatment of Autoimmune Diseases. | Wu, WC., et al. 2023. J Immunol Res. 2023: 8924603. PMID: 38106519
- Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency. | Liongue, C., et al. 2024. Int J Mol Sci. 25: PMID: 38474223
- Peficitinib alleviated acute lung injury by blocking glycolysis through JAK3/STAT3 pathway. | Jiang, W., et al. 2024. Int Immunopharmacol. 132: 111931. PMID: 38547769
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JAK3 Antibody (3F228) | sc-71461 | 200 µg/ml | $322.00 |